Drugs / BT7480
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05163041 | Nov 2021 → Aug 2026 overdue | neoplasm | BicycleTx Limited | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07681674 | Aug 2026 → May 2030 expected | cancer | BicycleTx Limited | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BT7480 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05163041 ↗ |
| Action | Activate | “tumor targeted immune cell agonist” NCT05163041 ↗ |
| Modality | Peptide | “three bicyclic peptides” NCT05163041 ↗ |
| Route | Intravenous | “60 minute IV infusion of BT7480” NCT05163041 ↗ |